The expression of extracellular carbonic anhydrases has stronger predictive power for survival of patients suffering from HER2-enriched breast cancer with low (HR = 0.441; Fig. 11H) than high (HR = 0.798; Fig. 11I) chronic inflammation signature. This evidence concerns the gene ERBB2 and breast carcinoma.